#syphilis

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

A new CDC analysis found that the syphilis rate among MSM is about 100 times higher than among men with only female partners.

It is unclear how going on Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) may have affected these rates.

However, might post-exposure prophylaxis (PEP) against STIs impact resistance to antibiotics among infections like gonorrhea?

A modeling study suggests that HIV meds’ effects on the immune response may partially explain the recent rise in syphilis in gay and bi men.

“Bicillin is the only treatment for pregnant women with syphilis, and Pfizer has the exclusive patent.”

Following a syphilis diagnosis, HIV-negative men who have sex with men at a London clinic contracted HIV at a high rate.

Syphilis cases spiked 333% since 2003, but a U.S. Senate bill wants to cut $5M from STD prevention.

Men who have sex with men (MSM) account for most new cases of gonorrhea and syphilis.

A considerable proportion of those diagnosed with the potentially blinding STI in North Carolina are simultaneously diagnosed with HIV.

The CDC’s first state-by state breakdown of rates of the STI among men who have sex with men reveals a heavy burden in the South.

The World Health Organization has recommended updated treatment protocols to combat drug-resistant gonorrhea, chlamydia and syphilis.

PrEP use and high STI rates are connected, but more research is needed to determine whether starting PrEP actually causes STI rates to rise.

People at high risk of syphilis, including men who have sex with men and people with HIV, should get tested every three months.

Nearly all of a group of people with HIV Warsaw diagnosed with early syphilis had neurosyphilis, which can contribute to cognitive decline.